ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

• DOI: 10.1371/journal.ppat.1008121
• Publication Date: 2019-12-03T18:25:03Z
• Authors: Luca Schifanella; Susan W. Barnett; Massimiliano Bissa; Veronica Galli; Melvin N. Doster; Monica Vaccari; Georgia D. Tomaras; Xiaoying Shen; Sanjay Phogat; Ranajit Pal; David C. Montefiori; Celia C. LaBranche; Mangala Rao; Hung V. Trinh; Robyn Washington-...; Namal P. M. Liyanage; Dallas R. Brown; Frank Liang; Karin Loré; David J. Venzon; William Magnanelli; Michelle Metrinko; Josh Kramer; Matthew Breed; Galit Alter; Ruth M. Ruprecht; Genoveffa Franchini
• Keywords: Alum

The ALVAC-HIV clade B/AE and equivalent SIV-based/gp120 + Alum vaccines successfully decreased the risk of virus acquisition in humans macaques. Here, we tested efficacy HIV B/C ALVAC/gp120 vaccine candidates MF59 or different doses Aluminum hydroxide (Alum) against SHIV-Cs varying neutralization sensitivity Low induced higher mucosal V2-specific IgA that increased Tier 2 SHIV-C acquisition. High dosage, contrast, elicited serum IgG to V2 correlated with a 1 negligible antibodies an inflammatory profile blood C-reactive Protein (CRP) levels correlating neutralizing antibody titers. relationship between challenge appear be linked immunological spaces created by via CXCL10 IL-1β, respectively.